Skip to main content
. Author manuscript; available in PMC: 2022 Jan 5.
Published in final edited form as: Cancer Res. 2020 Nov 6;81(2):332–343. doi: 10.1158/0008-5472.CAN-19-3922

Figure 2. ARID1A deletion sensitizes PDAC cells to NVP-AUY922.

Figure 2.

A. Growth inhibition assay of parental cells and ARID1A knock-out cells, measured as cell viability after treatment with NVP-AUY922 for 72 hours. Data represent mean ± SD (n=4). *, P <0.05. B. Clonogenic assay (top panel) and acetic acid assay (bottom panel) in parental cells and ARID1A knock-out cells after treatment with NVP-AUY922 for 14 days. Data represent mean ± SD (n=3). ***, P <0.001. C. Proliferation curves of parental cells and ARID1A knock-out cell lines treated or not with with NVP-AUY922. Data represent mean ± SD (n=6). ***, P <0.001; **, P <0.01; *, P <0.05. D. Annexin V apoptosis assay in parental cells and ARID1A knock-out cell lines treated or not with NVP-AUY922 for 48 hours. Data represent mean ± SD (n=3). ***, P <0.001; **, P <0.01.